TY - JOUR
T1 - MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis
AU - Glenn, Justin D.
AU - Pantoja, Itzy Morales
AU - Caturegli, Patrizio
AU - Whartenby, Katharine A.
N1 - Funding Information:
The work was funded in part by MYMD Pharmaceuticals and the Starwood Trust.
Funding Information:
Funding was provided by MyMD Pharmaceuticals and the Starwood Trust Foundation.
Publisher Copyright:
© 2019
PY - 2020/2/15
Y1 - 2020/2/15
N2 - Multiple sclerosis (MS) is an autoimmune disease that remains in need of effective therapies. Plant-derived medicines have appealing properties for the treatment of autoimmune diseases. MYMD-1 is a synthetic plant alkaloid that has been shown to ameliorate the course of autoimmune thyroiditis. The goal of the present study was to determine whether MYMD-1 would produce similar beneficial effects in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE) induced by immunization with myelin oligodendrocyte glycoprotein. MYMD-1 improved the course of EAE and suppressed activation of effector T cells without causing global immunosuppression or toxicity. These results suggest that MYMD-1 may be of interest for evaluating for the treatment of autoimmune diseases.
AB - Multiple sclerosis (MS) is an autoimmune disease that remains in need of effective therapies. Plant-derived medicines have appealing properties for the treatment of autoimmune diseases. MYMD-1 is a synthetic plant alkaloid that has been shown to ameliorate the course of autoimmune thyroiditis. The goal of the present study was to determine whether MYMD-1 would produce similar beneficial effects in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE) induced by immunization with myelin oligodendrocyte glycoprotein. MYMD-1 improved the course of EAE and suppressed activation of effector T cells without causing global immunosuppression or toxicity. These results suggest that MYMD-1 may be of interest for evaluating for the treatment of autoimmune diseases.
UR - http://www.scopus.com/inward/record.url?scp=85075368473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075368473&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2019.577115
DO - 10.1016/j.jneuroim.2019.577115
M3 - Article
C2 - 31778849
AN - SCOPUS:85075368473
SN - 0165-5728
VL - 339
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
M1 - 577115
ER -